-
VAXDYN
Created in 2011
-
-
Up & running (A)
Existing signals show a regular activity -
Social networks
1,977 -
Activities
-
Technologies
-
Entity types
-
Location
Av. Manuel Siurot, S/n, 41013 Sevilla, Spain
Sevilla
Spain
-
Employees
Scale: 2-10
Estimated: 12
-
Engaged catalyst
0
0 0 -
Added in Motherbase
1 year, 8 months ago
-
Value proposition
Vaccines against antibiotic-resistant infections
Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach.
Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).
Vaccines, Antimicrobial Resistance, and Superbugs
-
Inicio | Vaxdyn
Preventing the next global health crisis Our mission is to prevent and alleviate the global health crisis caused by the pathogenic bacteria resistant to ant ...
https://vaxdyn.com/
